Viking Therapeutics (VKTX) Cash from Financing Activities (2014 - 2026)
Viking Therapeutics' (VKTX) quarterly Cash from Financing Activities came in at $23.6 million in Q2 2026, up 4552.07% year-over-year from $507000.0 in Q2 2025, and up 95.3% quarter-over-quarter from $12.1 million in Q1 2026.
Powered by 
Analysis
Viking Therapeutics (VKTX) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Viking Therapeutics has disclosed Cash from Financing Activities across 13 years of filings, most recently posting $23.6 million for Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 4552.07% year-over-year to $23.6 million; the TTM figure through Jun 2026 stood at $111.2 million (up 2441.02% YoY), while the FY2025 annual figure was $76.4 million, down 87.52% from the prior year.
- Cash from Financing Activities came in at $23.6 million for Q2 2026 at Viking Therapeutics, up from $12.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $606.0 million in Q1 2024 to a low of -$5.0 million in Q1 2022.
- Average Cash from Financing Activities over 5 years is $55.6 million, with a median of $1.8 million recorded in 2024.
- Year-over-year, Cash from Financing Activities soared 22770.21% in 2022 and tumbled 840.0% in 2023.
- Over 5 years, Cash from Financing Activities stood at $10.7 million in 2022, then tumbled by 98.25% to $188000.0 in 2023, then soared by 431.91% to $1.0 million in 2024, then surged by 7410.3% to $75.1 million in 2025, then sank by 68.6% to $23.6 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $23.6 million in Q2 2026, $12.1 million in Q1 2026, and $75.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn | -47.00 Mn |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn | -1.48 Bn |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn | 2.34 Bn |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn | -3.66 Bn |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn | -426.70 Mn |
| 10 | Viking Therapeutics | 4.86 Bn | 4.86 Bn | - | 23.59 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.59 Mn |
| Mar 31, 2026 | 12.08 Mn |
| Dec 31, 2025 | 75.10 Mn |
| Sep 30, 2025 | 480,000.00 |
| Jun 30, 2025 | 507,000.00 |
| Mar 31, 2025 | 349,000.00 |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 2.52 Mn |
| Jun 30, 2024 | 2.91 Mn |
| Mar 31, 2024 | 606.04 Mn |
| Dec 31, 2023 | 188,000.00 |
| Sep 30, 2023 | -74,000.00 |
| Jun 30, 2023 | 267.08 Mn |
| Mar 31, 2023 | 4.18 Mn |
| Dec 31, 2022 | 10.75 Mn |
| Sep 30, 2022 | 10,000.00 |
| Jun 30, 2022 | -1.59 Mn |
| Mar 31, 2022 | -5.01 Mn |
| Dec 31, 2021 | 47,000.00 |
| Sep 30, 2021 | -256,000.00 |
API Access
Viking Therapeutics Cash from Financing Activities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=VKTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-from-financing-activities", "ticker": "VKTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=VKTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();